Mr. Bailey and Mr. Stewart Will Join Bausch
+ Lomb on April 24, 2023
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or
the “Company”), a leading global eye health company dedicated to
helping people see better to live better, announced the
appointments of Bob Bailey as executive vice president (EVP) and
Chief Legal Officer and Andrew Stewart as president, Ophthalmic
Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr.
Stewart will join the executive management team of the Company.
Concurrent with these appointments, Christina Ackermann will step
down from her role as EVP, General Counsel and president,
Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April
28, 2023.
“Bob Bailey and Andrew Stewart both bring more than 25 years of
unrivaled leadership and expertise in their respective areas. Bob
is a talented leader and legal strategist with experience that
spans across the health care industry. Andrew has a highly proven
track record of developing and commercializing pharmaceutical
products that meet unmet needs in eye health,” said Brent Saunders,
chairman and CEO, Bausch + Lomb. “Having worked with Bob and Andrew
for the past several years, I am confident they will create value
for Bausch + Lomb and help position the Company for long-term
success.”
“I am excited to return to Bausch + Lomb, where I proudly served
for 18 years earlier in my career,” said Mr. Bailey. “I look
forward to working with this leadership team and my colleagues on
the legal and compliance teams to contribute to the Company’s
bright future.”
“Bausch + Lomb has a comprehensive product portfolio and
innovative pipeline in Ophthalmic Pharmaceuticals,” said Mr.
Stewart. “I am eager to work with Brent and the team to bolster the
Company’s prescription medicines business and find new solutions
that meet the evolving needs of the eye care professionals and
patients around the world who rely on Bausch + Lomb.”
“Additionally, I’d like to thank Christina Ackermann for her
service and tireless dedication to the Company. Under her
leadership, Bausch + Lomb and its parent company successfully
addressed a broad range of litigation, corporate, intellectual
property and regulatory matters and expanded the depth of our
Ophthalmic Pharmaceuticals portfolio,” continued Mr. Saunders.
About Bob Bailey
Bob Bailey has over 25 years of experience as a senior executive
and more than 15 years as a chief legal officer at private and
publicly traded companies in the health care industry, including
formerly serving as EVP, Law, Policy and Communications at Bausch +
Lomb from 2007 to 2013. He will rejoin Bausch + Lomb from Datavant,
a private health information technology company, where he has most
recently served as Chief Legal Officer. Previously, he served as
EVP, Chief Legal Officer and Corporate Secretary of Allergan plc
and its predecessor companies, Forest Laboratories Inc. and Actavis
plc. At Allergan, he led a legal team that closed more than 20
public and private M&A transactions, as well as several
licensing arrangements. During his career, he also has led teams
that defended and resolved a range of complex legal and regulatory
matters, including investigations by the U.S. Securities and
Exchange Commission and the U.S. Department of Justice; internal
investigations; and intellectual property, antitrust, commercial,
product liability and tax matters. Mr. Bailey began his legal
career as an attorney at Nixon Peabody LLP before moving to Bausch
+ Lomb in 1994.
Until recently, Mr. Bailey served as a director of TearClear, an
innovator in the ophthalmic pharmaceuticals field, and as a member
of the Board of Directors of the U.S. Chamber of Commerce
Litigation Center. He received his bachelor’s degree from St. Olaf
College and his J.D. from the University of Minnesota.
About Andrew Stewart
Andrew Stewart has more than 25 years of experience in the
pharmaceutical industry. He will join Bausch + Lomb from AbbVie,
where he has most recently served as general manager within the Eye
Care franchise. At AbbVie and its predecessor company, Allergan
plc, Mr. Stewart also previously had responsibility for the U.S.
Retina business; led global marketing for the Eye Care franchise;
and oversaw business development initiatives for the Eye Care
franchise. Earlier in his career, Mr. Stewart served at Bristol
Meyers Squibb for nearly 14 years in Global Clinical Operations and
Pharmaceutical Development Operations of the R&D department and
at Merck & Co., Inc. for 7 years in the manufacturing
division.
Mr. Stewart obtained an MBA from the New York University Stern
School of Business, a master’s degree in Environmental Science from
Rutgers University and a bachelor’s degree in Chemical Engineering
from the New Jersey Institute of Technology.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift
of sight for millions of people around the world – from the moment
of birth through every phase of life. Its comprehensive portfolio
of more than 400 products includes contact lenses, lens care
products, eye care products, ophthalmic pharmaceuticals,
over-the-counter products and ophthalmic surgical devices and
instruments. Founded in 1853, Bausch + Lomb has a significant
global research and development, manufacturing and commercial
footprint with approximately 13,000 employees and a presence in
nearly 100 countries. Bausch + Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more
information, visit www.bausch.com and connect with us on Twitter,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words “anticipates,”
“hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,”
“may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties associated with our
ability to attract, retain and motivate our executives and other
key employees and risks and uncertainties caused by or relating to
the evolving COVID-19 pandemic, and the fear of that pandemic and
its potential effects, the severity, duration and future impact of
which are highly uncertain and cannot be predicted, and which may
have a material adverse impact on Bausch + Lomb, including but not
limited to its project development timelines, launches and costs
(which may increase). Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
+ Lomb undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
© 2023 Bausch & Lomb Incorporated or its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230412005353/en/
Investor: Arthur Shannon arthur.shannon@bausch.com
Allison Ryan allison.ryan@bausch.com (877) 354-3705 (toll free)
(908) 927-0735
Media: Lainie Keller lainie.keller@bausch.com (908)
927-1198
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024